News | November 25, 2021
Cadila partners with Enzychem of South Korea to manufacture ZyCoV-D
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Suchirayu owns a state-of-the-art multi-speciality hospital in Hubli with an operational capacity of 110 beds and a potential to scale up to 250 beds
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
The system is a compact new addition to the Roche Molecular portfolio, providing efficiency, simplicity and timely results to laboratories of all sizes.
The final data from the trial showed sotrovimab reduces hospitalisation and risk of death by 79% in adults with mild-to-moderate Covid-19 who are at high risk of progression to severe disease
Launching in 2022, its availability will be expanded to the global market
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
Subscribe To Our Newsletter & Stay Updated
